This site is intended for healthcare professionals

News

Phase II DESTINY-CRC01 trial of Enhertu/Enhurtu demonstrated meaningful activity in patients with HER2 positive unresectable and/or metastatic colorectal cancer.- Daiichi Sankyo + AstraZeneca

Read time: 1 mins

Last updated:2nd Jun 2020

Published:2nd Jun 2020

Condition: Colorectal Cancer

Type: drug

Register free for full access to medthority.com

Click here to register now